openPR Logo
Press release

Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) -- By ALD Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH)

Global Fatty Liver Disease Drugs Market

Global Fatty Liver Disease Drugs Market

A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global Fatty Liver Disease Market on the basis of Type (Alcoholic Fatty Liver Disease or ALD), Non Alcoholic Fatty Liver Disease or NAFLD), By Alcoholic Fatty Liver Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis), By Non Alcoholic Fatty Liver Stages (Non Alcoholic Steatosis, Non Alcoholic Steatohepatitis or NASH), By Alcoholic Liver Disease Drug (Opiod Antagonist, Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor), By Non Alcoholic Fatty Liver Drug (Antioxidants Thiazolidinedione, Biguanides, Lipid Lowering agents, FXR receptor agonist, Elafibranoer), By Region (North America, Europe, Asia Pacific and ROW) and By Country (U.S., Canada , U.K., France, Germany, China, Japan, India, Brazil, South Africa and Saudi Arabia).

Over the recent years, the global fatty liver disease incidence has been growing rapidly with increase in prevalence of obesity, type II diabetes along with rising consumption of alcohol. Globally, the growth in the fatty liver disease market is driven by rising awareness among people by government organizations and private companies, heavy investments by pharmaceutical companies for the development of drugs along with launch of drugs for NASH in the forecasted period.

According to Azoth Analytics research report, the report “Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) - By ALD Stages (Alcoholic Steatosis ,Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH)” analyses the Global Fatty Liver Disease Market, Analysis By Type (Alcoholic Fatty Liver Disease or ALD), Non Alcoholic Fatty Liver Disease or NAFLD), By Alcoholic Fatty Liver Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis or ASH), By Non Alcoholic Fatty Liver Stages (Non Alcoholic Steatosis, Non Alcoholic Steatohepatitis or NASH), By Alcoholic Liver Disease Drug (Opiod Antagonist, Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor) and By Non Alcoholic Fatty Liver Drug (Antioxidants Thiazolidinedione, Biguanides, Lipid Lowering agents, FXR receptor agonist, Elafibranoer). The global market is projected to display a robust growth represented by a CAGR of 22.67% during 2017 – 2022, chiefly driven by rising prevalence of obesity, diabetes and hypertension, rising clinical trials in Asian countries, heavy investments by government of different countries in their health care sector, rising research in developing the different health care machines and methodology for the detection of alcohol and non-alcohol steatosis at its early stage.

The report titled, “Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) - By ALD Stages (Alcoholic Steatosis ,Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH)” has covered and analysed the potential of Global Fatty Liver Disease Market, NASH and NAFLD markets and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global fatty liver disease market. Additionally, the report also highlights market entry strategies for various companies across the globe.

Scope of the Report

Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)
• Fatty Liver Disease market
• Breakdown –By NAFLD Stages (2012-2022): (Steatosis , NASH)
• Breakdown –By ALD Stages (2012-2022): (Steatosis, Alcohol Hepatitis)
• Breakdown by ALD Drugs (2012-2022): (Opioid Antagonist ,Glucocorticoid, Pentoxifyline, Antioxidants, Granulocyte colony stimulating factor)
• Breakdown By NAFLD Drug (2012-2022): (Antioxidants Thiazolidinedione, Biguanides, Hypolipidemic Agents, FXR receptor agonist, Elafibranoer)

Regional Markets – North America, Europe, APAC, ROW (Actual Period: 2012-2016 Forecast Period: 2017-2022)
• Fatty Liver Disease market
• Fatty Liver Disease market By Type (ALD, NAFLD)
• Breakdown by ALD Drugs (2012-2022)
• Breakdown By NAFLD Drug (2012-2022)

Country Analysis - UK, Germany, France, India, China, Japan, Brazil, Saudi Arabia, South Africa, U.S. and Canada – (Actual Period: 2012-2016, Forecast Period: 2017-2022)
• Fatty Liver Disease market
• Fatty Liver Disease market By Type (ALD, NAFLD)

Other Report Highlights
• Market Dynamics – Trends, Drivers, Challenges
• Policy and Regulation
• Company Analysis – Pfizer, Gilead Sciences ,Astra Zenca, Immuron, Novartis,Takeda, Allergan , Intercept Pharmaceuticals, Conatus

Customization of the Report

The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.

Azoth Analytics is a business research and analytics firm that creates in-depth research reports and provides customized research solutions and consultancy services. Verticals in which Azoth Analytics specializes include healthcare and pharmaceutical, oil and gas, retail, chemicals, automotive, FMCG, food & beverages and technology. Azoth creates comprehensive and in-depth research reports by recording, interpreting and analyzing information. Strategic market sizing and data dredging techniques include secondary research, and primary research (interviews with management personnel and industry experts).

CS – 55, Third Floor, Ansal Plaza, Vaishali,
Ghaziabad U.P., India
Mail: info@azothanalytics.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Fatty Liver Disease Drugs Market By Type (ALD, NAFLD), By Stages of ALD and NAFLD, By Region, By Country: Opportunities and Forecast (2017-2022) -- By ALD Stages (Alcoholic Steatosis, Alcoholic Steatohepatitis), By NAFLD Stages (Steatosis, NASH) here

News-ID: 651042 • Views: 448

More Releases from Azoth Analytics Pvt. Ltd.

Global Dairy Ingredients Market Analysis
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of dairy ingredients market. The report analyses the Global Dairy Ingredients Market- By Source (Whey and Milk Based), By Production Method (Membrane Separation and Traditional Method), By Type (Milk Powders, Milk Proteins, Whey Ingredients, Casein and Caseinates, Lactose and Derivatives and Others) and By Application
Global Medical Cannabis Market - Analysis By Product Type (Cannabis Indica, Cann …
Globally, the market for Medical Cannabis has been growing on a swift pace on the back of escalating application of cannabis in a number of industries ranging from healthcare to Food and Beverage. Additionally, government in major countries are focusing on legalizing the medical application of cannabis keeping under consideration the medicinal benefits associated with cannabis supported by burgeoning demand for high quality, organic cannabis globally which is the reason
Global LNG Carrier Containment Market Forecast (2014-2024)
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global LNG Carrier Containment Market. The Global LNG Carrier Containment market has been analysed By Carrier Type (Moss Type, Membrane Type), By Propulsion Type(Steam Reheat, ME-GI, DFDE, SSD Steam, TFDE, XDF, Others), By Capacity (30,000-124,999cm, 125,000-149,999cm, 150,000-180,000cm, >180,000cm). The Global LNG Carrier Containment market
Global Blood Plasma Market
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis Global Blood Plasma Market. The report analyses the Blood Plasma Market By Type (Immunoglobulins- IV+SC, Albumin, Factor VIII- Plasma Derived, and Others), By Region (North America, Europe, Asia Pacific, Rest of the World) and By Country (U.S, Canada, Germany, France, Italy, China, Japan, India, Australia,

All 5 Releases


More Releases for Liver

Global Liver Detox Market Research Report
This report studies the global Liver Detox market status and forecast, categorizes the global Liver Detox market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia). The major manufacturers covered in this report Health Plus(UK) Swisse(AU) ReNew Life Formulas, Inc.(US) NATURE' S BOUNTY(US) Healthy Care(AU) Evolution Slimming Ltd(UK) PureFormulas Inc.
Liver Cirrhosis - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Liver Cirrhosis - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Cirrhosis - Pipeline Review, H1 2017, provides an overview of the Liver Cirrhosis (Gastrointestinal) pipeline landscape. Cirrhosis is scarring of the liver caused by many forms of liver diseases and conditions, such as hepatitis and
Liver Transplant Rejection - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Liver Transplant Rejection - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Liver Transplant Rejection - Pipeline Review, H1 2017, provides an overview of the Liver Transplant Rejection (Immunology) pipeline landscape. Liver transplantation is the conventional therapy used in various liver diseases. Liver has the unique ability
Global Liver Disease Treatment Market
The Liver Disease Treatment Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies. The liver is one of the most important organs of the human body and performs major functions, such as removal of harmful substances from blood, maintains adequate level of chemicals
Liver Extract Power Exporter, Liver Extract Product, Liver Extract Crude, Liver …
Titan Biotech is an ISO 9001:2000 Certified Company, established with an objective of serving Scientific Community and providing good quality of Biological Products, Biotechnology Products, Biological Extracts and their derivatives. Liver Extract Power Exporter is produced from specific fraction of beef liver. Liver Extract is rich in vital nutrients including energy producing B Vitamins and serve as an excellent source of proteins. Liver Extract is capable of stimulating the production
Liver Disease Diagnostics by Immunoblot Test System
Mainz based ORGENTEC Diagnostika GmbH has developed a new immunoblot test for the serological diagnosis of autoimmune liver disease. Liver-9-Line facilitates the rapid and cost-effective diagnosis of autoimmune hepatitis (type 1 and type 2 AIH) and primary biliary cirrhosis (PBC) in a single step. The test system also allows for the reliable differentiation of these autoimmune diseases from other diseases of the liver. This immunoblot is suitable for initial and differential